注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
NextCure Inc是一家临床阶段的生物制药公司,专注于发现和开发新型免疫药物,通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。通过其专有的功能性,集成性,NextCure Discovery in Immuno-Oncology (FIND-IO) 平台,公司正在研究各种免疫细胞,以发现和了解免疫细胞的靶标和结构成分及其功能影响,以开发免疫药物。其候选产品包括 NC318、NC410、NC762 和 NC 525。NC318是一种针对新型免疫调节蛋白Siglec-15的免疫药物。NC410是一种新型免疫药物,旨在阻断由称为白细胞相关免疫球蛋白样受体的免疫调节剂介导的免疫抑制。NC762是一种针对称为人B7同源物4蛋白的免疫调节分子的免疫药物。NC525是一种新型LAIR-1抗体,选择性靶向急性髓系白血病。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Michael S. Richman | 61 | 2015 | Co-Founder, CEO, President & Director |
Mario Sznol | 64 | - | Member of Scientific Advisory Board |
Stephen D. Miller | - | - | Member of Scientific Advisory Board |
Stephen W. Webster | 61 | 2019 | Independent Director |
David S. Kabakoff | 74 | 2015 | Independent Chairman of the Board |
Elaine V. Jones | 67 | 2015 | Independent Director |
Lieping Chen | 64 | 2015 | Co-Founder & Chairman of Scientific Advisory Board |
Chau Quang Khuong | 46 | 2015 | Independent Director |
John G. Houston | 63 | 2020 | Independent Director |
Anne Elizabeth Borgman-Hagey | 55 | 2021 | Independent Director |
Weiping Zou | - | 2021 | Member of Scientific Advisory Board |
Ellen Gwen Feigal | 69 | 2021 | Independent Director |
Brahm Segal | - | 2022 | Member of Scientific Advisory Board |
Lisa M. Coussens | - | 2022 | Member of Scientific Advisory Board |
Ursula A. Matulonis | - | 2021 | Member of Scientific Advisory Board |
Rakesh Dixit | - | 2024 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核